论文部分内容阅读
目的:评价重组人血管内皮抑制素+吉西他滨+顺铂治疗老年性晚期非小细胞肺癌(NSCLC)的有效性和安全性。方法:将2007年1月至2010年12月在辽宁省肿瘤医院住院的72例老年性晚期NSCLC患者分为两组,其中研究组(重组人血管内皮抑制素+吉西他滨+顺铂)患者40例;对照组(吉西他滨+顺铂)患者32例,两组患者均至少完成2个周期的治疗。评价两组患者总有效率、临床获益率和不良反应发生情况。结果:研究组和对照组患者有效率、临床获益率分别为42.5%和28.1%、80.0%和56.2%,两组比较,差异有统计学意义(P<0.05);研究组和对照组患者骨髓抑制、胃肠道反应、肝肾功能损害发生率分别为37.5%和37.5%、12.5%和12.5%、7.5%和6.2%,两组比较,差异无统计学意义(P>0.05)。结论:重组人血管内皮抑制素+吉西他滨+顺铂治疗老年性晚期NSCLC是一种有效、安全的方案。
Objective: To evaluate the efficacy and safety of recombinant human endostatin + gemcitabine plus cisplatin in the treatment of senile advanced non-small cell lung cancer (NSCLC). Methods: Seventy-two elderly patients with advanced NSCLC who were hospitalized in Liaoning Provincial Cancer Hospital from January 2007 to December 2010 were divided into two groups. Among them, 40 patients in the study group (recombinant human endostatin + gemcitabine plus cisplatin) ; Control group (gemcitabine + cisplatin) in 32 patients, both groups of patients completed at least 2 cycles of treatment. The total effective rate, clinical benefit rate and adverse reactions in both groups were evaluated. Results: The effective rate and clinical benefit rate of the study group and the control group were 42.5% and 28.1%, 80.0% and 56.2%, respectively, with significant difference between the two groups (P <0.05). The study group and the control group The incidence of myelosuppression, gastrointestinal reaction and liver and kidney dysfunction were 37.5% and 37.5%, 12.5% and 12.5%, 7.5% and 6.2% respectively. There was no significant difference between the two groups (P> 0.05). Conclusion: Recombinant human endostatin + gemcitabine + cisplatin is an effective and safe treatment for senile advanced NSCLC.